N-(tert-butyloxycarbonyl)-2-ethyl-5-carbethoxy-1,2,3,6-tetrahydropyridine | 134420-83-0

• 分子结构分类: 有机化合物 - 生物碱及其衍生物
• 英文名称: N-(tert-butyloxycarbonyl)-2-ethyl-5-carbethoxy-1,2,3,6-tetrahydropyridine
• 英文别名: 1-O-tert-butyl 5-O-ethyl 2-ethyl-3,6-dihydro-2H-pyridine-1,5-dicarboxylate
• CAS: 134420-83-0
• 化学式: C₁₅H₂₅NO₄
• 分子量: 283.368
• InChiKey: KLQPMJNKUBPNLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(tert-butyloxycarbonyl)-2-ethyl-5-carbethoxy-1,2,3,6-tetrahydropyridine 在 盐酸 作用下， 反应 2.0h， 以60%的产率得到2-ethyl-5-carbethoxy-1,2,3,6-tetrahydropyridine hydrochloride
  参考文献：
  名称：

  GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative

  摘要：

  A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1-mu-M. This value is as good as those of the best GABA-uptake inhibitors known today.

  DOI：

  10.1021/jm00112a032
• 作为产物：
  描述：

  4-Acetoxy-6-ethyl-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 在 1,5-二氮杂双环[4.3.0]壬-5-烯 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以80%的产率得到N-(tert-butyloxycarbonyl)-2-ethyl-5-carbethoxy-1,2,3,6-tetrahydropyridine
  参考文献：
  名称：

  GABA-uptake inhibitors: construction of a general pharmacophore model and successful prediction of a new representative

  摘要：

  A model for the pharmacophore of GABA-uptake inhibitors was established using published structure-activity data and molecular modeling. The model accounted for the activities of different classes of GABA-uptake inhibitors. Analogues of guvacine substituted at position 6 were synthesized in order to confirm the model. 6-(3,3-Diphenylpropyl)guvacine (30f), which fit well with the pharmacophore, had an in vitro IC50 of 0.1-mu-M. This value is as good as those of the best GABA-uptake inhibitors known today.

  DOI：

  10.1021/jm00112a032

文献信息

• CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：EP3336088A1

  公开（公告）日：2018-06-20

  Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, crystalline forms I-IV of the compound and preparation method thereof, and application of the crystalline forms in preparation of a drug treating a disease associated with orexin.

  本发明公开了一种奥曲肽受体拮抗剂化合物5-3的制备方法、该化合物的结晶形式I-IV及其制备方法，以及该结晶形式在制备治疗与奥曲肽相关疾病的药物中的应用。
• Crystal form of orexin receptor antagonist compound, and preparation method and application thereof
  申请人：Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

  公开号：US10874674B2

  公开（公告）日：2020-12-29

  Disclosed is a preparation method of an orexin receptor antagonist compound 5-3. Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of preparing crystalline forms of the orexin receptor antagonist compound 5-3, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease.

  本发明公开了一种奥曲肽受体拮抗剂化合物 5-3 的制备方法。提供了奥曲肽受体拮抗剂化合物 5-3 的结晶形式 I-IV。还提供了制备奥曲肽受体拮抗剂化合物 5-3 结晶形式的工艺，以及使用结晶形式 I-IV 治疗奥曲肽相关疾病的方法。